专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006037762A1 METHOD FOR EX-VIVO PURGING IN AUTOLOGOUS TRANSPLANTATION 审中-公开
标题翻译：在自动移植中进行血液透析的方法
公开(公告)号：WO2006037762A1
公开(公告)日：2006-04-13
申请号：PCT/EP2005/054950
申请日：2005-09-30
申请人： APOXIS SA , DUPUIS, Marc , GREANEY, Peter , DUCHOSAL, Michel
发明人： DUPUIS, Marc , GREANEY, Peter , DUCHOSAL, Michel
IPC分类号： C12N5/16
CPC分类号： C12N5/0093
摘要： The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address.
摘要翻译：本发明涉及一种在自体移植中离体清除细胞的新方法，其中用足够数量的多聚体形式的FasL的可溶性部分处理所取细胞的样品以杀死恶性细胞，而不会基本上影响细胞的活力被移植。大剂量放化疗后的自体干细胞移植（ASCT）已经成为大多数大细胞淋巴瘤，多发性骨髓瘤和难治性/复发性霍奇金病患者的标准治疗方法。对于低度淋巴瘤（慢性淋巴细胞白血病，滤泡淋巴瘤，套细胞淋巴瘤）和急性骨髓性白血病（AML）患者，目前也考虑了这种治疗方法。目前用于细胞清除的治疗方法包括化疗和抗体鸡尾酒。这些治疗通常对干细胞是有毒的，并且不能有效地消除癌细胞。因此，本项目将针对ASCT中的细胞清除未满足的医疗需求。

2. 发明申请

WO03022867A3 PEPTIDES DERIVED FROM THE SUPERANTIGEN (SAG) ENV PROTEIN OF HERV-K18 AND THEIR USE IN OBTAINING SAG-INHIBITORY ANTIBODIES AND IN VACCINATION AGAINST SAG 审中-公开
标题翻译：从HERV-K18的超级（SAG）ENV蛋白衍生的肽及其用于获得SAG抑制抗体和针对SAG的疫苗
公开(公告)号：WO03022867A3
公开(公告)日：2003-09-04
申请号：PCT/EP0211049
申请日：2002-09-06
申请人： NOVIMMUNE SA , DUPUIS MARC
发明人： DUPUIS MARC
IPC分类号： A61K39/00 , A61K39/21 , A61P37/00 , C07K14/15 , C07K16/10 , C12N15/48 , A61K39/42
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/505 , A61K2039/545 , A61K2039/55566 , A61K2039/575 , A61K2039/6081 , C07K16/1036 , C12N2740/10022 , C12N2740/10034
摘要： The present invention relates to peptides derived from the superantigen (Sag) ENV protein of the human endogenous retrovirus HERV-K18, and to the use of the peptides in obtaining antibodies which inhibit the superantigen activity of HERV-K18 ENV. The invention also relates to vaccine compositions for treating and preventing disorders associated with the ENV gene product of HERV-K18, for example autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM). A preferred peptide consists of a portion of an N- or C-terminal segment of the HERV-K18.1 ENV protein, as illustrated in Figure 1A, said N-terminal segment extending from amino acids 22 to 62 of HERV-K18.1 ENV, and said C-terminal segment extending from amino acids 110 to 153 of HERV-K18.1 ENV, wherein the peptide has a length of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 envelope proteins.
摘要翻译：本发明涉及源自人内源性逆转录病毒HERV-K18的超抗原（Sag）ENV蛋白的肽，以及该肽在获得抑制HERV-K18 ENV的超抗原活性的抗体中的用途。本发明还涉及用于治疗和预防与HERV-K18的ENV基因产物相关的病症的疫苗组合物，例如自身免疫性疾病如胰岛素依赖性糖尿病（IDDM）。优选的肽由HERV-K18.1 ENV蛋白的N-或C-末端片段的一部分组成，如图1A所示，所述N末端片段从HERV-K18.1的氨基酸22至62延伸 ENV和从HERV-K18.1 ENV的氨基酸110至153延伸的所述C-末端片段，其中所述肽具有6至40个氨基酸的长度，并且能够产生抑制与HERV相关的超抗原活性的抗体 -K18包膜蛋白。

3. 发明申请

WO2003022867A2 PEPTIDES DERIVED FROM THE SUPERANTIGEN (SAG) ENV PROTEIN OF HERV-K18 AND THEIR USE IN OBTAINING SAG-INHIBITORY ANTIBODIES AND IN VACCINATION AGAINST SAG 审中-公开
标题翻译：衍生自HERV-K18的超抗原（SAG）ENV蛋白的肽以及它们在获得SAG-抑制性抗体和对抗SAG的疫苗中的用途
公开(公告)号：WO2003022867A2
公开(公告)日：2003-03-20
申请号：PCT/EP2002/011049
申请日：2002-09-06
申请人： NOVIMMUNE S.A. , DUPUIS, Marc
发明人： DUPUIS, Marc
IPC分类号： C07K
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/505 , A61K2039/545 , A61K2039/55566 , A61K2039/575 , A61K2039/6081 , C07K16/1036 , C12N2740/10022 , C12N2740/10034
摘要： The present invention relates to peptides derived from the superantigen (Sag) ENV protein of the human endogenous retrovirus HERV-K18, and to the use of the peptides in obtaining antibodies which inhibit the superantigen activity of HERV-K18 ENV. The invention also relates to vaccine compositions for treating and preventing disorders associated with the ENV gene product of HERV-K18, for example autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM). A preferred peptide consists of a portion of an N- or C-terminal segment of the HERV-K18.1 ENV protein, as illustrated in Figure 1A, said N-terminal segment extending from amino acids 22 to 62 of HERV-K18.1 ENV, and said C-terminal segment extending from amino acids 110 to 153 of HERV-K18.1 ENV, wherein the peptide has a length of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 envelope proteins.
摘要翻译：本发明涉及源自人内源性逆转录病毒HERV-K18的超抗原（Sag）ENV蛋白的肽，并且涉及该肽在获得抑制HERV-K18的超抗原活性的抗体中的用途， K18 ENV。本发明还涉及用于治疗和预防与HERV-K18的ENV基因产物有关的病症的疫苗组合物，例如自身免疫疾病如胰岛素依赖性糖尿病（IDDM）。如图1A所示，优选的肽由HERV-K18.1Ev蛋白的N-或C-末端片段的一部分组成，所述N-末端片段从HERV-K18.1的氨基酸22至62延伸 ENV，并且所述C端片段从HERV-K18.1 ENV的氨基酸110至153延伸，其中所述肽具有6至40个氨基酸的长度并且能够产生抑制与HERV相关的超抗原活性的抗体 -K18包膜蛋白。

4. 发明申请

WO2006077232A3 MULTIMERIC SOLUBLE FAS LIGAND FOR ELIMINATING ALLOREACTIVE T LYMPHOCYTE IN ALLOGENIC HARMATOPOIETIC STEM-CELL TRANSPLANTATION TRANSPLANTATION 审中-公开
公开(公告)号：WO2006077232A3
公开(公告)日：2006-07-27
申请号：PCT/EP2006/050300
申请日：2006-01-19
申请人： APOXIS SA , DUPUIS, Marc , DEMOTZ, Stéphane , GREANEY, Peter , ATTINGER, Antoine , PERROD, Séverine
发明人： DUPUIS, Marc , DEMOTZ, Stéphane , GREANEY, Peter , ATTINGER, Antoine , PERROD, Séverine
IPC分类号： A61K38/17 , A61K38/19 , A61P37/06
摘要： The present invention concerns novel approaches for eliminating activated allo-reactive T lymphocyte in vivo and in vitro, preventing GVHD development with a sufficient amount of a multimeric form of the soluble portion of FasL as defined below.

5. 发明申请

WO2006077232A2 MULTIMERIC SOLUBLE FAS LIGAND FOR ELIMINATING ALLOREACTIVE T LYMPHOCYTE IN ALLOGENIC HARMATOPOIETIC STEM-CELL TRANSPLANTATION TRANSPLANTATION 审中-公开
标题翻译：多功能可溶性FAS配体，用于消除嗜血性淋巴细胞移植中的分泌性淋巴细胞移植
公开(公告)号：WO2006077232A2
公开(公告)日：2006-07-27
申请号：PCT/EP2006050300
申请日：2006-01-19
申请人： APOXIS SA , DUPUIS MARC , DEMOTZ STEPHANE , GREANEY PETER , ATTINGER ANTOINE , PERROD SEVERINE
发明人： DUPUIS MARC , DEMOTZ STEPHANE , GREANEY PETER , ATTINGER ANTOINE , PERROD SEVERINE
IPC分类号： A61K38/17 , A61K38/19 , A61P37/06
CPC分类号： A61K38/177 , A61K38/1709
摘要： The present invention concerns novel approaches for eliminating activated allo-reactive T lymphocyte in vivo and in vitro, preventing GVHD development with a sufficient amount of a multimeric form of the soluble portion of FasL as defined below.
摘要翻译：本发明涉及在体内和体外消除活化的同种异体反应性T淋巴细胞的新方法，用足够量的多聚体形式的FasL的可溶性部分防止GVHD发展，如下所定义。

6. 发明申请

WO2005117966A1 METHOD TO REDUCE HEPATOTOXICITY OF FAS-MEDIATED APOPTOSIS-INDUCING AGENTS 审中-公开
标题翻译：减少FAS介导的病毒诱导剂的致肝毒性的方法
公开(公告)号：WO2005117966A1
公开(公告)日：2005-12-15
申请号：PCT/EP2005/052436
申请日：2005-05-27
申请人： APOXIS SA , DUPUIS, Marc , DEMOTZ, Stéphane , GOEDKOOP, René
发明人： DUPUIS, Marc , DEMOTZ, Stéphane , GOEDKOOP, René
IPC分类号： A61K39/395
CPC分类号： C07K16/241 , A61K2039/505
摘要： The invention concerns a method to prevent or reduce adverse effects on liver of a patient treated with a Fas-mediated apoptosis-inducing agent, the method comprising the administration of a product preventing TNF receptors-mediated apoptosis of the liver cells.
摘要翻译：本发明涉及一种预防或减少用Fas介导的凋亡诱导剂治疗的患者对肝脏的不利影响的方法，该方法包括施用预防TNF受体介导的肝细胞凋亡的产物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式